{"id":205669,"name":"FRESENIUS KABI USA LLC","slug":"fresenius-kabi-usa-llc","state":"IL","country":"United States of America","description":"","totalSpending":4449749.03,"filings":29,"yearlySpending":[{"year":2019,"income":0},{"year":2020,"income":75000},{"year":2021,"income":100000},{"year":2022,"income":100000},{"year":2023,"income":962895.35},{"year":2024,"income":1333912.6800000002},{"year":2025,"income":1877941}],"issues":["TRD","CPT","TAX","PHA","MMM","DIS","MAN","ACC","LBR","BUD","MED","SCI","HCR","TAR"],"firms":["FRESENIUS KABI USA LLC"],"lobbyists":["SARAH D'ORSIE","TIMOTHY CASEY","STEVEN WALKER","CRAIG BURTON","STU EVENHAUGEN","CHRIS LEIBUNDGUTH"],"govEntities":["Centers For Medicare and Medicaid Services (CMS)","Food & Drug Administration (FDA)","Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE","White House Office","Patent & Trademark Office (PTO)","Commerce, Dept of (DOC)","Executive Office of the President (EOP)","U.S. Trade Representative (USTR)","Office of Management & Budget (OMB)","Labor, Dept of (DOL)","Defense, Dept of (DOD)"],"sampleDescriptions":["BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S","BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S","BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S","BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S","BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S"],"years":[2019,2020,2021,2022,2023,2024,2025]}